Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Bendandi M, et al. Leuk Lymphoma. 2006 Jan;47(1):29-37. doi: 10.1080/10428190500272473. Leuk Lymphoma. 2006. PMID: 16321824 Clinical Trial.
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group. Inogès S, et al. Among authors: bendandi m. J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301. doi: 10.1093/jnci/djj358. J Natl Cancer Inst. 2006. PMID: 16985248 Clinical Trial.
Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M. Inoges S, et al. Among authors: bendandi m. Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122. Leuk Lymphoma. 2009. PMID: 19152172 Free article.
Stem cell transplant and idiotypic vaccination for B-cell malignancies.
Inoges S, Lopez-Diaz de Cerio A, Sampol A, Nieto J, Soria E, Villanueva H, Pastor F, Bendandi M. Inoges S, et al. Among authors: bendandi m. Curr Top Med Chem. 2011;11(13):1653-60. doi: 10.2174/156802611796117676. Curr Top Med Chem. 2011. PMID: 21446912 Free article. Review.
Idiotype vaccines for lymphoma therapy.
Inogés S, de Cerio AL, Villanueva H, Soria E, Pastor F, Bendandi M. Inogés S, et al. Among authors: bendandi m. Expert Rev Vaccines. 2011 Jun;10(6):801-9. doi: 10.1586/erv.11.44. Expert Rev Vaccines. 2011. PMID: 21692701 Free article. Review.
Idiotype vaccine production using hybridoma technology.
Inoges S, de Cerio AL, Villanueva H, Pastor F, Bendandi M. Inoges S, et al. Among authors: bendandi m. Methods Mol Biol. 2014;1139:367-87. doi: 10.1007/978-1-4939-0345-0_30. Methods Mol Biol. 2014. PMID: 24619694
[Past, present and future of anti-idiotype vaccination].
Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, Pérez Calvo J, Prósper F, Melero I, Sánchez-Ibarrola A, Rocha E, Bendandi M. Rodríguez Calvillo M, et al. Among authors: bendandi m. Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23. Rev Med Univ Navarra. 2004. PMID: 15622921 Review. Spanish.
Anti-idiotype antibodies in cancer treatment.
de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. de Cerio AL, et al. Among authors: bendandi m. Oncogene. 2007 May 28;26(25):3594-602. doi: 10.1038/sj.onc.1210371. Oncogene. 2007. PMID: 17530013 Free article. Review.
128 results